OXULAR
Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
OXULAR
Industry:
Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oxular.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1865 636200
Email Addresses:
[email protected]
Total Funding:
76.71 M USD
Technology used in webpage:
SPF LetsEncrypt Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Bizland StratLogic DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
SONE Health
SONE Health is an Italian company born from an intuition of its founders about the mechanical functionality of the classic stethoscope!
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Sapiens Steering Brain Stimulation
Sapiens is a medical device company that delivers solutions for deep brain stimulation therapy.
PlusDental
PlusDental is a Berlin-based Health-Tech Startup in the area of digital dentistry.
Current Advisors List
Current Employees Featured
Founder
Investors List
IP Group
IP Group investment in Series B - Oxular
Neomed Management
Neomed Management investment in Series B - Oxular
V-Bio Ventures
V-Bio Ventures investment in Series B - Oxular
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Oxular
V-Bio Ventures
V-Bio Ventures investment in Series A - Oxular
Imperial Innovations
Imperial Innovations investment in Series A - Oxular
Consort Medical
Consort Medical investment in Series A - Oxular
Imperial Innovations
Imperial Innovations investment in Series A - Oxular
Official Site Inspections
http://www.oxular.com
- Host name: 2.27.214.35.bc.googleusercontent.com
- IP address: 35.214.27.2
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Oxular"
About Us – Oxular
V-Bio Ventures finds, builds, and finances innovative life sciences companies. The company invests throughout Europe in start-up and early-stage companies with high growth potential as …See details»
Oxular - Crunchbase Company Profile & Funding
Organization. Oxular . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the …See details»
Oxular - LinkedIn
Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular ...See details»
Oxular Company Profile 2024: Valuation, Funding & Investors
Oxular General Information Description. Operator of a retinal therapeutics company intended to offer retinal disease treatment. The company offers tissue-specific delivery of potent drug …See details»
Oxular Company Profile - Office Locations, Competitors, Revenue …
Oxular is an ophthalmic company developing drug and device combination treatments for retinal disease. Its product development pipeline includes treatments for such diseases as age …See details»
Oxular’s Novel Technology Has Potential to Change …
Nov 1, 2023 Oxular Limited was formed to develop suprachoroidal space therapies, integrating optimized drug products and its novel delivery device, Oxulumis®. Our company’s goal is to develop long-lasting ...See details»
Oxular raises $37 million - Markets Insider
Mar 1, 2021 The OXU-001 program will combine the use of Oxular's highly adaptable, disruptive technologies including: · Oxuspheresâ„¢ – A proprietary drug-containing biodegradable polymer …See details»
Oxular Limited Announces Acceptance of IND for
Jan 24, 2023 Oxular is a biotechnology company developing long-lasting retinal treatments, delivered suprachoroidally, to improve patients’ vision so they can live better lives. The company has engineered ...See details»
Oxular raises $37 million - PR Newswire
Mar 1, 2021 Oxular raises $37 million Led by specialist life sciences investor, Forbion. Investment will fund Phase 2 human clinical studies evaluating Oxular's 12-month treatment …See details»
Partnering – Oxular
Oxular is actively partnering with industry peers to utilize the potential of our technology across multiple modalities and indications. Creating value through relationships. Oxular’s technologies were developed together to find solutions …See details»
Oxular Limited - Oxular Doses First Patients in OXEYE Phase 2 …
Oct 24, 2023 Oxular is a biotechnology company developing safe, long-lasting suprachoroidal retinal treatments to improve patients’ vision so they can live better lives. The company has …See details»
Oxular Receives Rare Paediatric Disease and Orphan-Drug …
Oct 12, 2020 Oxular's OXU-003 programme for the treatment of retinoblastoma consists of a proprietary anti-tumour drug which utilises Oxular's formulation and ocular administration …See details»
OXU-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 About Oxular Oxular is a biotechnology company developing long-lasting retinal treatments, delivered suprachoroidally, to improve patients’ vision so they can live better lives. …See details»
Our technology – Oxular
Oxular’s technologies were developed together to find solutions that would solve significant remaining unmet challenges in retinal care. Together, these systems will transform the …See details»
Oxular | EU-Startups
Oxular's sustained-release formulations are designed to work in specific small regions in the eye and persist up to a year after a single injection. This method delivers a one-of-a-kind and exact …See details»
Oxular advancing once-per-year DME treatment with $37M series B
Mar 1, 2021 LONDON – Oxular Ltd. has raised $37 million in a series B, enabling the company to take OXU-001, its long-acting treatment for diabetic macular edema (DME) into phase II …See details»
About Us - Oxular
V-Bio Ventures finds, builds, and finances innovative life sciences companies. The company invests throughout Europe in start-up and early-stage companies with high growth potential as …See details»
Technology - Oxular
Oxular is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Oxular’s significant innovation is the combination of: …See details»
Pipeline - Oxular
Our high-value, near-term pipeline uses our innovative technology to create differentiated product candidates with the potential to transform the treatment paradigm for retinal disorders.See details»